Since BCL-2 overexpression is a common finding in leukemias and lymphomas and because apoptosis blockage is a fundamental carcinogenic mechanism in lymphoid malignancies (7, 12)BCL-2 is considered a key therapeutic target. This evidence concerns the gene BCL2 and leukemia.